南模生物(688265) - 2025 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of approximately 42,125.86 million RMB, representing a year-on-year increase of 10.50%[2] - The net profit attributable to shareholders of the parent company was approximately 3,243.13 million RMB, a significant year-on-year increase of 399.29%[2] - The net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was approximately 940.81 million RMB, marking a turnaround from a loss in the previous year[2] - Basic earnings per share increased to 0.43 RMB, up 436.11% compared to the previous year[2] - The weighted average return on net assets rose to 1.91%, an increase of 1.53 percentage points year-on-year[2] Assets and Equity - Total assets at the end of the reporting period were 198,204.66 million RMB, reflecting a 2.73% increase from the beginning of the period[2] - The equity attributable to shareholders of the parent company was 171,005.16 million RMB, up 1.61% from the beginning of the period[2] Factors Influencing Performance - The company attributed its performance improvement to a recovery in the domestic biopharmaceutical industry and effective cost control measures[7] - Government subsidies and other non-recurring income contributed to the increase in net profit[8] Financial Data Disclaimer - The company emphasizes that the financial data is preliminary and subject to audit, urging investors to be aware of investment risks[9]